Compare KZIA & ZSQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KZIA | ZSQR |
|---|---|---|
| Founded | 1994 | 2022 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 204.6M |
| IPO Year | 2002 | 2020 |
| Metric | KZIA | ZSQR |
|---|---|---|
| Price | $9.49 | $3.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.36 | N/A |
| AVG Volume (30 Days) | 297.9K | ★ 375.9K |
| Earning Date | 11-06-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,363,045.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $2.11 |
| 52 Week High | $17.40 | $16.62 |
| Indicator | KZIA | ZSQR |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 58.36 |
| Support Level | $9.01 | $2.81 |
| Resistance Level | $14.85 | $4.64 |
| Average True Range (ATR) | 0.70 | 0.47 |
| MACD | -0.05 | 0.26 |
| Stochastic Oscillator | 18.83 | 79.36 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.